Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3results about How to "Has inhibitory effect" patented technology

Heterocyclic compounds, pharmaceutical compositions comprising the same, and methods of use thereof

The application provides artemordins A-S (compounds 1-19), a pharmaceutical composition thereof, and a preparation method and application thereof, and belongs to the technical field of drugs. The 19 sesquiterpene dimers shown in structural formula (I) of the application have cytotoxic activity on human hepatoma cell strains HepG2, Huh7 and SK-Hep-1, can be combined with a pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition, and can be used for preparing an anti-hepatoma drug.
Owner:KUNMING INST OF BOTANY CHINESE ACAD OF SCI

Enterococcus hirae C01, probiotic agent and application thereof

PendingCN122648297AHas inhibitory effectEnhanced inhibitory effect
The present application relates to the technical field of microorganism, and especially relates to Enterococcus hirae C01, probiotic agent and application thereof.The present application provides the Enterococcus hirae C01, and the preservation number is CGMCC No.33994.The strain has broad-spectrum bacteriostatic activity, can inhibit Salmonella enteritidis, Salmonella pullorum and Salmonella typhimurium, has no hemolytic activity, has good stress resistance, can survive in gastrointestinal environment, and has high biological safety, and can be used for preventing and controlling mixed Salmonella infection in clinic.
Owner:HEBEI AGRICULTURAL UNIV. +1

Composite polymer bacteriostatic agent, preparation method and application

PendingCN122074484AReservation of mildnessEffective antibacterial concentration decreases
This invention specifically relates to a composite polymer antibacterial agent, its preparation method, and its application, belonging to the field of antibacterial materials technology. The antibacterial agent, by weight percentage, comprises a core component PQ-1 (0.01%~0.1%), a synergistic component polyhexamethylene biguanide (PHMB) (0.005%~0.05%), a synergistic component polyaminopropyl biguanide (PAPB) (0.005%~0.05%), and the balance being solvent. This invention, through the synergistic combination of PQ-1 and the two synergistic components, can reduce the minimum inhibitory concentration (MIC) against typical microorganisms by more than 75% while reducing the amount of PQ-1 by 50%~80%, achieving optimized protection of the antibacterial efficacy concentration of PQ-1, while also possessing the advantages of broad spectrum, stability, mildness, and low toxicity. Its preparation process is simple and can be widely applied in ophthalmic preparations, cosmetics, and other fields, demonstrating extremely high practical value.
Owner:SHANDONG SHENLIAN PHARM CO LTD +2